Efficacy of Tamsulosin 0.4 mg versus 0.8 mg in the treatment of lower urinary tract symptoms associated with benign prostatic enlargement

According to a new study, Tamsulosin 0.8 mg has demonstrated superior efficacy in managing lower urinary tract symptoms caused by benign prostatic enlargement compared to Tamsulosin 0.4 mg, and it is well tolerated by patients. This study was published in the journal, International Urology and Nephrology. 
In this study, ninety-three patients who met the criteria were allocated randomly into two groups: Group A, who received Tamsulosin 0.4 mg/day, and Group B, who received Tamsulosin 0.8 mg/day. The post void residual urine volume, international prostate symptom score and maximum flow rate of urine were measured before and after 4 weeks of treatment
Both study groups exhibited a notable decline in storage sub-score but only Group B demonstrated a significant decrease in frequency (P < 0.001).Tamsulosin 0.8 mg was found to be superior to Tamsulosin 0.4 mg in terms of voiding sub-score, except for straining (P = 0.325). The total international prostate symptom score exhibited a significant improvement in Group B when compared to Group A (P < 0.001). Additionally, maximum flow rate and post-void residual urine volume were notably improved in Group B when compared to Group A (P < 0.001).
Thus, it can be concluded that Tamsulosin 0.8 mg is more effective than Tamsulosin 0.4 mg in addressing lower urinary tract symptoms caused by benign prostatic enlargement, and patients tolerate it well.